---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001219"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:18:50.440015+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma receives Nasdaq bid-price deficiency notice; board committee changes

## Summary
- On Feb 27, 2024, Nasdaq notified CNS Pharma common stock bid price closed below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
- Company has 180 days until Aug 26, 2024 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.
- This follows a prior delisting notice for failing to meet $2.5M stockholders' equity; hearing requested and stay granted.
- Board appointed committee chairs: Audit (Keyes), Compensation (Gumulka), Nominating/Governance (Cockroft) effective Feb 21, 2024.

## SEC filing metadata
- accession: 0001683168-24-001219
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824001219/0001683168-24-001219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824001219/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001219
- JSON: https://secwatch.observer/filing/0001683168-24-001219.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001219.txt

## Key facts
- Listing & Compliance Notices
  CNS Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: February 27, 2024, CNS Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq Listing Rule 58
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824001219/0001683168-24-001219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.